Renaissance Pharma Ltd 14519863 false 2022-12-02 2023-12-31 2023-12-31 The principal activity of the company is Research and exp develop on biotechnology Digita Accounts Production Advanced 6.30.9574.0 true 14519863 2022-12-02 2023-12-31 14519863 2023-12-31 14519863 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 14519863 bus:Micro-entities 2022-12-02 2023-12-31 14519863 bus:AuditExemptWithAccountantsReport 2022-12-02 2023-12-31 14519863 bus:FullAccounts 2022-12-02 2023-12-31 14519863 bus:SmallCompaniesRegimeForAccounts 2022-12-02 2023-12-31 14519863 bus:RegisteredOffice 2022-12-02 2023-12-31 14519863 bus:Director3 2022-12-02 2023-12-31 14519863 bus:Director4 2022-12-02 2023-12-31 14519863 bus:Director5 2022-12-02 2023-12-31 14519863 bus:PrivateLimitedCompanyLtd 2022-12-02 2023-12-31 14519863 countries:EnglandWales 2022-12-02 2023-12-31 iso4217:GBP xbrli:pure

Registration number: 14519863

Renaissance Pharma Ltd

Unaudited Financial Statements

for the Period from 2 December 2022 to 31 December 2023

 

Renaissance Pharma Ltd

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

2

 

Renaissance Pharma Ltd

Company Information

Directors

B M Ash

E J Johnson

A M Webb

Registered office

8a Crabtree Road
Egham
Surrey
TW20 8RN

 

Renaissance Pharma Ltd

(Registration number: 14519863)
Balance Sheet as at 31 December 2023

2023
£

Fixed assets

53,963

Current assets

581,309

Prepayments and accrued income

1,476

Creditors: Amounts falling due within one year

(270,865)

Net current assets

311,920

Total assets less current liabilities

365,883

Accruals and deferred income

(139,056)

 

226,827

Capital and reserves

226,827

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
8a Crabtree Road
Egham
Surrey
TW20 8RN

These financial statements were authorised for issue by the Board on 29 November 2024.

Basis of preparation

The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

2

Staff numbers

The average number of persons employed by the company (including directors) during the period, was 2.

3

Related party transactions

Included in creditors at 31 December 2023 is a loan of £11,881 received from a director. Included in debtors is £1,496 due from a company controlled by a director. Interest accrues daily on each loan at the rate of 2% per annum. Each loan, together with accrued interest, is repayable in full on the earlier of (i) a share sale; (ii) an asset sale; or (iii) an insolvency event occuring in respect of the Company.

For the financial period ending 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

 

Renaissance Pharma Ltd

(Registration number: 14519863)
Balance Sheet as at 31 December 2023

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 29 November 2024 and signed on its behalf by:
 

.........................................
B M Ash
Director